MegaStream TechBio Emerges as AI-Powered Drug Discovery 'Superfactory' with Filing of IPO Prospectus
Harbour BioMed
Antibody Drug Developer
BioMap
Developer of Innovative Drug R&D Platform
In this era, the old is crumbling while the new is emerging.
WhenSpaceXSurged on the First Day of Listing2With a trillion-dollar market capitalization, what Musk has unleashed is not merely a space opera exploring the vast cosmos, but also an earth-shattering explosionAICloud. The familiar old world crumbled, silicon-based andAIThe sci-fi aesthetic being shaped is becoming a fresh reality.
The singularity of innovative drugs has also arrived, with past R&D models constrained by“Inverse Moore's Law”, approximately every9years, the R&D costs will double, and all of this will beAIDisruption.
6Month15Day, Shanghai, aAIA pharmaceutical super factory has emerged.
Harbour BioMed and BioMap Join Forces to Co-establish a NewAIPipeline R&D CompanyMegaStream TechBio, this is a historic moment as the global leading platform for drug development meets the most powerful foundational large model for life sciences, markingAIPharmaceutical manufacturing has transitioned from technical suspension to the stage of industrial implementation.
MegaStreamThe mission of a Gigafactory is mass production.FIC/BICComplex Macromolecule Pipeline, with the following operational workflow:First, establish a world-class exclusiveAIDD Infrastructure Platform,Harbour BioMed offers globally uniqueHarbour Mice®The vast amount of high-quality data accumulated by the fully human antibody platform, combined with BioMap’s globally leading foundational large model for life sciencesxTrimo V4(Benchmarking NVIDIABioNeMo, GoogleDeepMind AlphaFold), forming a self-evolving capabilityMegaStreamPersonalized Proprietary Large Language Model;then withMegaStreamEstablishing a New Generation of Intelligent High-Throughput Dry-Wet Closed-Loop Laboratories Based on Large Models,EstimatedAI Enhanced Efficiency of Native Molecular Validation500%Above, data accumulation efficiency increased by more than10times;The result is the scaled-up production of a new generation of high-quality pipeline molecules,Finally completed the clinical trial by Harbour BioMed+Operations.
MegaStreamFunctioning as a pipeline factory, forming fromAIThe complete value chain closed loop from R&D to clinical implementation, with a monetization model ofBDor divest the pipeline, with both parties sharing potential upfront payments, success-based milestones, and royalty interests in accordance with industry practice.
MegaStreamwill be implemented and operationalized at the fastest possible speed, running through from a practical combat stanceAIAn Innovative Closed-Loop from Design to Clinical Validation.
01
Unprecedented Implementation Intensity
Action, act now.
In our “AIPharmaceutical Hidden Champion: Why Harbour BioMed?》points out, “2026, will beAI"A Major Year for the Large-Scale Commercialization of Pharmaceuticals."
The sound of footsteps landing is everywhere.
6Month11On [date], Takeda Pharmaceutical announced a new generation of oralTYK2InhibitorZasocitinibIn the treatment of moderate-to-severe plaque psoriasisIIIdefeated head-to-head in the phase studyBMSDrugs with the Same TargetSotyktuIt is worth noting that,Zasocitinibis Takeda Pharmaceutical Company40acquired with a down payment of hundreds of millions of US dollars byAIThe success of this head-to-head trial of the small-molecule inhibitor designed by the pharmaceutical company also marksAIA Victory for Manual Molecular Synthesis by Humans.
6Month10Day, ByteDanceAIPharmaceutical Spin-off Officially Launches Separation and Independent Fundraising Process, Signifying That ByteDance Is Pushing a Long-Term Incubated Cutting-Edge Technology Business Line to the External Market and Entering the Industrialization Phase, Also MeaningAIThe pharmaceutical industry enters an arms race phase.
AIThe window of opportunity for the pharmaceutical industry has opened. The wheel of time waits for no one; the scale and depth of the collaboration between Harbour BioMed and BioMap are unprecedented.
First, the joint venture entity is bound.Beyond TraditionAIThe loose, single-project collaboration paradigm between enterprises and innovative pharmaceutical companies, with both parties establishing independent R&D companiesMegaStream TechBio, and Harbour BioMed will serve as the lead initiator, forMegaStreamLeveraging its globally unique fully human antibody platform, extensive target biology expertise, and global clinical development advantages, BioMap will serve as a co-initiator, providing the underlyingAI Technology enablement, model engineering support, and intelligent R&D capabilities. Both parties also made comprehensive arrangements for the distribution of benefits from pipeline outputs.
Second, long-cycle, full-chain translation and commercialization.From fragmented early-stage molecular design collaborations, scaled up to hundreds ofFIC/BIC Large-scale R&D of the pipeline, leveraging Harbour BioMed’s clinical development and operational capabilities to bridge the gap fromAIGenerate a complete chain leading to clinical value, and implement an industrial closed loop from early-stage research to commercial monetization.
Time Waits for No One: Harbour BioMed atAIPharmaceuticals: Multi-line Layout and Repeated Investment Increases.
Harbour BioMed's FirstAICandidate Drugs This Year5Yuedu has delivered outstanding preclinical data, leveragingHu-mAtrIx™Next-Generation Targeted Therapeutics Developed by the AI PlatformACVR2A/2BMonoclonal Antibody DrugsLET003, exhibiting superior pharmacokinetic profiles compared to multiple competitor molecules. When used in combination with semaglutide,LET003Significantly enhances fat loss effects and effectively preserves lean body mass. At lower doses,LET003can achieve efficacy comparable to that of higher dosesbimagrumabSignificant promotion of lean body mass increase, demonstrating its potential in the treatment of obesityBICPotential.
The joint founding of thisMegaStream, is Harbour BioMedAIPart of a larger puzzle, involvingHarbour Mice®Harbour BioMed’s exclusive high-quality antibody data, which remains a core asset of Harbour BioMed, is licensed by Harbour BioMed toMegaStreamUse.
02
World-Class AIDD Infrastructure Platform
AITechnologically Reversible“Inverse Moore's Law”。
According to Deloitte’s “Evaluation of Returns on Pharmaceutical Innovation,” the overall return on R&D investment in the biopharmaceutical sector, since2010Annual10.1%Continued decline,2024Annual maintenance of approximately4.1%level.
AIis evolving from a standalone tool into the underlying infrastructure of the R&D and production system. According to NVIDIA’s public information,AITechnology demonstrates significant advantages across all stages of drug development, reducing the time required in the early discovery phase to one-third of the original duration and lowering costs to 1/200th, with the overall cycle for drug discovery and preclinical research shortened by nearly40%; According toTechEmergenceData,AITechnology can increase the success rate of new drug development in the clinical phase from12%Increased to approximately14%。
AIThe Chinese Solution for Pharmaceutical Manufacturing Is Here.
Harbour BioMed holds the world’s largest fully human heavy-chain antibody database.Data resources areAICore production factors in the upstream pharmaceutical industry chain, whose quality and abundance directly determine the prediction accuracy and generalization ability of models. Harbour BioMed possesses globally leadingHarbour Mice®Fully human antibody technology platform and a vast amount of high-quality antibody data accumulated over more than ten years, which particularly covers functional, druggability, safety, and clinical data in the mid-to-late stages of antibody discovery. These proprietary data assets constitute the trainingAIModel ingredients can support the full-chain algorithm development from target discovery to clinical prediction.
BioMap is the global leader in foundational large models for life sciences.its independently developed2680billion-parameterxTrimo V4Large models achieve greater accuracy by decoding the underlying principles of genes, proteins, cells, and biological systemsAIPredictive capability, already in20and other subfields of life sciences300achieved industry-leading performance across multiple prediction tasks (SOTA) performance, and won the championship of the first World Virtual Cell Challenge.
Proprietary High-Quality Antibody Data+Life Science Foundation Large Model, CatalyzingMegaStreamA personalized, dedicated large model, systematically trained, optimized, and iterated in a targeted manner to address the distinct characteristics of complex macromolecular drugs versus conventional generic protein and antibody therapeutics.
Two Powerhouses Join Forces to Create a World-ClassAIDriving Complex Macromolecular DrugsAIDD Infrastructure Platform,Focused on next-generation multispecific antibodies,XDCConjugated Drugs, In VivoCAR-T. Inhalation/Deep optimization of complex macromolecules, such as oral biologics, delivers robust performance advantages, enabling an end-to-end workflow from sequence generation to developability optimization.AIDesign Capability.
03
Scaled Production of Pipeline Assets
OnceAIDDInfrastructure Platform/Successfully developed a dedicated large model, forming“Data-Model”Positive Feedback Effect: The Rise of Next-Generation Superfactories for Complex Macromolecules Will Be Unstoppable.
According to Huachuang Securities, leading overseas companies are beginning to shift toward automated wet-lab experiments to build data flywheels, for exampleRecursionSelf-built intelligent laboratory, operating approximately weekly220Ten Thousand Experiments, Passed“AIDesign-Robot Execution-Real-time Feedback”closed-loop system that autonomously generates high-quality proprietary data in a standardized, high-throughput manner, transforming from a data consumer to a data producer and gradually reducing reliance on public datasets.
Harbour BioMed and BioMap willMegaStreamBuilt on a proprietary large language model, we are co-developing a new generation of intelligent high-throughput dry-wet closed-loop laboratory, with its efficiency expected to improve compared to the previous generation of dry-wet closed-loop laboratories.500%The above will significantly accelerate the discovery and iteration pace of complex macromolecular drugs, paving the way for a fundamental transformation in R&D paradigms andAI provides strong support for the continuous optimization of model capabilities. Meanwhile,AIThe Native Intelligence Lab will increase data accumulation efficiency by more than10times,It is expected to generate more than in the next five years5PBHigh QualityAI-ReadyLife Science Data, DrivingAIModels are rapidly evolving.
Thus,AIThe R&D engine is established, and a new generation of pipeline portfolios will surge forth.
The First of Both PartiesAI+Biotechnology-DrivenFICPipeline R&D collaboration commenced in2021years, and subsequently10participated in pipeline attribute prediction, optimization, and generative design during the R&D process of multiple pipelines. In the future, leveraging the newly built next-generationAIComplex Macromolecule Drug R&D Platform, Focusing on Major Unmet Clinical Needs in Cardiovascular, Renal, Anti-Aging, and Oncology Fields,FIC/BICThe R&D capabilities of the pipeline will be significantly enhanced, for Harbour BioMed andMegaStreamProvides solid support for advancing hundreds of innovative pipeline projects in parallel.MegaStreamApprovedAIBy combining model predictions with a small amount of high-precision validation to replace traditional repetitive screening experiments, and leveraging the generative predictive advantages of large models, this approach yields high-quality pipeline molecules with superior performance metrics, more comprehensive attribute optimization, and more precise programmable controllability.
MegaStreamCompany establishment and the implementation of the first batch of pipelines will be completed in the shortest time possible.. Its core management team will be jointly formed by senior executives from multinational pharmaceutical companies and top experts in the field of artificial intelligence, with relevant personnel gradually taking their positions; the initial pipeline consists of projects from the parties' previous collaborationsAI Drug R&D Projects and Newly InitiatedAIThe joint development of native pipeline projects will accelerate the process of clinical translation.
Conclusion
In the face of epochal changes, all anxieties actually stem from maladaptation. Nassim, author of The Black Swan·Taleb this year2Yue posted a tweet with just one sentence:“20All professions invented in the century are inescapableAIimpact.”
"Be diligent all day long, and advance with the times."
Harbour BioMed possesses a keen sense of industry trends and forward-looking vision, with the inherent capacity for self-evolution and platform advancement ingrained in its DNA.
Exclusive Big Data×Exclusive Large Language Model×Large innovative pipeline portfolio,MegaStreamforAIborn from the integration of strong resources, with the potential to become a global leader in complex macromoleculesAIA Benchmark Enterprise in Drug R&D.
